The purpose of this review is to summarize essential pharmacological, pharmaceutical, and
clinical aspects in the field of orally inhaled therapies that may help scientists seeking to …

Rationale: Eradication and suppression of Pseudomonas aeruginosa is a key priority in
national guidelines for bronchiectasis and is a major focus of drug development and clinical …

CT scanning can also aid in identifying an aetiology of bronchiectasis eg Allergic
bronchopulmonary aspergillosis (ABPA), Non-tuberculous mycobacteria (NTM), primary …

Bronchiectasis in adults is a chronic disorder associated with poor quality of life and frequent
exacerbations in many patients. There have been no previous international guidelines. The …

Background Chronic airway inflammation is the main driver of pathogenesis in respiratory
diseases such as severe asthma, chronic obstructive pulmonary disease, cystic fibrosis (CF) …

Rationale: Exacerbations are key events in the natural history of bronchiectasis, but clinical
predictors and outcomes of patients with frequently exacerbating disease are not well …

Background and objective The aim of the Pulmonary Rehabilitation Guidelines (Guidelines)
is to provide evidence‐based recommendations for the practice of pulmonary rehabilitation …

Background Chronic respiratory disease causes substantial global morbidity and mortality.
The contribution of pulmonary tuberculosis to the aetiology of chronic respiratory disease is …

Background Post-tuberculosis lung damage (PTLD) is a recognised consequence of
pulmonary TB (pTB). However, little is known about its prevalence, patterns and associated …

Bronchiectasis is a multidimensional disease and, therefore, its severity or prognosis cannot
be adequately quantified by analysing one single variable. The objective of the present …